Publications:

---

JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Frontiers In Cell And Developmental Biology

Downes, Charlotte Ej CE; McClure, Barbara J BJ; McDougal, Daniel P DP; Heatley, Susan L SL; Bruning, John B JB; Thomas, Daniel D; Yeung, David T DT; White, Deborah L DL

Publication Date: 2022

Variant appearance in text: JAK2: L884P

PubMed Link: 35903543

Variant Present in the following documents:

• Main text
• fcell-10-942053.pdf

View BVdb publication page

---

Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia.

Science Advances

Barsan, Valentin V; Xia, Yuntao Y; Klein, David D; Gonzalez-Pena, Veronica V; Youssef, Sarah S; Inaba, Yuki Y; Mahmud, Ousman O; Natarajan, Sivaraman S; Agarwal, Vibhu V; Pang, Yakun Y; Autry, Robert R; Pui, Ching-Hon CH; Inaba, Hiroto H; Evans, William W; Gawad, Charles C

Publication Date: 2022-04-22

Variant appearance in text: JAK2: L884P

PubMed Link: 35442732

Variant Present in the following documents:

• sciadv.abj1360.pdf

View BVdb publication page

---

Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Cancers

Bochicchio, Maria Teresa MT; Di Battista, Valeria V; Poggio, Pietro P; Carrà, Giovanna G; Morotti, Alessandro A; Brancaccio, Mara M; Lucchesi, Alessandro A

Publication Date: 2022-02-15

Variant appearance in text: JAK2: L884P

PubMed Link: 35205715

Variant Present in the following documents:

• Main text
• cancers-14-00972.pdf

View BVdb publication page

---

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.

Npj Precision Oncology

Downes, Charlotte E J CEJ; McClure, Barbara J BJ; Bruning, John B JB; Page, Elyse E; Breen, James J; Rehn, Jacqueline J; Yeung, David T DT; White, Deborah L DL

Publication Date: 2021-08-10

Variant appearance in text: JAK2: L884P

PubMed Link: 34376782

Variant Present in the following documents:

• Main text
• 41698_2021_Article_215.pdf

View BVdb publication page

---

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Cells

Grabek, Julian J; Straube, Jasmin J; Bywater, Megan M; Lane, Steven W SW

Publication Date: 2020-08-14

Variant appearance in text: JAK2: L884P

PubMed Link: 32823933

Variant Present in the following documents:

• cells-09-01901.pdf

View BVdb publication page

---

De novo primary central nervous system pure erythroid leukemia/sarcoma with t(1;16)(p31;q24) NFIA/CBFA2T3 translocation.

Haematologica

Liu, Huifei H; Guinipero, Terri L TL; Schieffer, Kathleen M KM; Carter, Chris C; Colace, Susan S; Leonard, Jeffrey R JR; Orr, Brent A BA; Kahwash, Samir B SB; Brennan, Patrick J PJ; Fitch, James R JR; Kelly, Benjamin B; Magrini, Vincent J VJ; White, Peter P; Wilson, Richard K RK; Mardis, Elaine R ER; Cottrell, Catherine E CE; Boué, Daniel R DR

Publication Date: 2020-04

Variant appearance in text: JAK2: 2651T>C; Leu884Pro

PubMed Link: 31949013

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.

Scientific Reports

Chuang, Yu-Chung YC; Huang, Bo-Yen BY; Chang, Hsin-Wen HW; Yang, Chia-Ning CN

Publication Date: 2019-08-06

Variant appearance in text: JAK2: L884P

PubMed Link: 31388026

Variant Present in the following documents:

• 41598_2019_Article_46825.pdf

View BVdb publication page

---

Importance of Incorporating Protein Flexibility in Molecule Modeling: A Theoretical Study on Type I1/2 NIK Inhibitors.

Frontiers In Pharmacology

Shen, Chao C; Liu, Hui H; Wang, Xuwen X; Lei, Tailong T; Wang, Ercheng E; Xu, Lei L; Yu, Huidong H; Li, Dan D; Yao, Xiaojun X

Publication Date: 2019

Variant appearance in text: JAK2: L884P

PubMed Link: 31024312

Variant Present in the following documents:

• fphar-10-00345.pdf

View BVdb publication page

---

Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

The Journal Of Allergy And Clinical Immunology

Hammarén, Henrik M HM; Virtanen, Anniina T AT; Abraham, Bobin George BG; Peussa, Heidi H; Hubbard, Stevan R SR; Silvennoinen, Olli O

Publication Date: 2019-04

Variant appearance in text: JAK2: L884P

PubMed Link: 30092288

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients.

Haematologica

Jain, Nitin N; Lu, Xinyan X; Daver, Naval N; Thakral, Beenu B; Wang, Sa A SA; Konoplev, Sergej S; Patel, Keyur K; Kanagal-Shamanna, Rashmi R; Valentine, Marcus M; Tang, Guilin G; Pemmaraju, Naveen N; Jorgensen, Jeffrey J; Kebriaei, Partow P; Nunez, Cesar A CA; Wierda, William W; Jabbour, Elias E; Roberts, Kathryn G KG; Mullighan, Charles G CG; Kantarjian, Hagop H; Konopleva, Marina M

Publication Date: 2017-12

Variant appearance in text: JAK2: L884P

PubMed Link: 28860345

Variant Present in the following documents:

• Main text

View BVdb publication page

---

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.

Scientific Reports

Kong, Xiaotian X; Sun, Huiyong H; Pan, Peichen P; Li, Dan D; Zhu, Feng F; Chang, Shan S; Xu, Lei L; Li, Youyong Y; Hou, Tingjun T

Publication Date: 2017-08-22

Variant appearance in text: JAK2: L884P

PubMed Link: 28831147

Variant Present in the following documents:

• Main text
• 41598_2017_9586_MOESM1_ESM.pdf
• 41598_2017_Article_9586.pdf

View BVdb publication page

---

The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Cytokine

Senkevitch, Emilee E; Durum, Scott S

Publication Date: 2017-10

Variant appearance in text: JAK2: L884P

PubMed Link: 28277287

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

The Journal Of Biological Chemistry

Losdyck, Elisabeth E; Hornakova, Tekla T; Springuel, Lorraine L; Degryse, Sandrine S; Gielen, Olga O; Cools, Jan J; Constantinescu, Stefan N SN; Flex, Elisabetta E; Tartaglia, Marco M; Renauld, Jean-Christophe JC; Knoops, Laurent L

Publication Date: 2015-11-27

Variant appearance in text: JAK2: L884P

PubMed Link: 26446793

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Cancer Cell

Wu, Shuo-Chieh SC; Li, Loretta S LS; Kopp, Nadja N; Montero, Joan J; Chapuy, Bjoern B; Yoda, Akinori A; Christie, Amanda L AL; Liu, Huiyun H; Christodoulou, Alexandra A; van Bodegom, Diederik D; van der Zwet, Jordy J; Layer, Jacob V JV; Tivey, Trevor T; Lane, Andrew A AA; Ryan, Jeremy A JA; Ng, Samuel Y SY; DeAngelo, Daniel J DJ; Stone, Richard M RM; Steensma, David D; Wadleigh, Martha M; Harris, Marian M; Mandon, Emeline E; Ebel, Nicolas N; Andraos, Rita R; Romanet, Vincent V; Dölemeyer, Arno A; Sterker, Dario D; Zender, Michael M; Rodig, Scott J SJ; Murakami, Masato M; Hofmann, Francesco F; Kuo, Frank F; Eck, Michael J MJ; Silverman, Lewis B LB; Sallan, Stephen E SE; Letai, Anthony A; Baffert, Fabienne F; Vangrevelinghe, Eric E; Radimerski, Thomas T; Gaul, Christoph C; Weinstock, David M DM

Publication Date: 2015-07-13

Variant appearance in text: JAK2: L884P

PubMed Link: 26175414

Variant Present in the following documents:

• Main text

View BVdb publication page

---